KMT2A and prostate cancer: The presence of the MLL1‐TTC36 fusion in one of the normal samples may indicate a significant risk for as yet undetected prostate cancer in this individual, since truncated MLL fusions are known to have an oncogenic effect (Dobson et al., 2000; Wachter et al., 2014).